Using genome sequencing & machine learning to modernize infectious disease diagnosis and treatment
Antibiotic resistance is creating a public health crisis. Patients with a severe infection can die within hours, but current diagnostics for antibiotic resistance take 2 days or longer. At DZD, we are developing a rapid, whole genome sequencing-based diagnostic that identifies the strain and antibiotic resistance profile of a bacterial infection within hours. Our machine learning algorithm Keynome™ uses MicrohmDB™, a proprietary microbial resistance database, to determine antibiotic resistance from genomic data. In a severe infection, faster treatment with the right antibiotic saves lives and reduces costs.
We are based at the Harvard Life Lab and Harvard iLab and we have a strong collaboration with the lab of Dr. Doug Kwon at the Ragon Institute of MGH, MIT and Harvard.
President & CEO, Co-founder
Medical technology entrepreneur. Formerly management consultant at Monitor Group, focused on medtech commercialization, and Senior VP of Marketing & Strategy at ConforMIS. BA from Harvard and MBA from Harvard Business School.
Computational biologist with expertise in genomics and machine learning. After MIT Physics undergrad, earned Harvard Applied Math PhD developing theory and computational methods for analyzing biological systems and large genomic datasets.
Infectious Disease physician at Mass. General Hospital (MGH), Assistant Professor at Harvard Medical School and a Director of Clinical Research at the Ragon Institute of MGH, MIT and Harvard. Expertise in the microbiome and its effect on immune response.
Clinical Pathology resident at MGH with expertise in immunology, the human microbiome, and diagnostics. After biomedical engineering degree at MIT, studied immunology on a Rhodes Scholarship in Oxford, and worked in Doug Kwon’s lab through the Harvard MD-PhD Program.
Software engineer with a physics and machine learning background. In his PhD at Harvard, Dougal worked on Bayesian methods and deep learning, and developed Autograd, a popular machine learning library.
Director, Product Development
Molecular microbiologist with expertise in bacterial physiology and genetics. Nicole's post-doc at MIT focused on bacterial biofilms, and she later contributed as a technical lead to the development of a rapid pathogen identification assay at Draper Labs.
Senior Research Scientist
Molecular biologist with expertise in molecular diagnostics and epigenetics. Yael's post-doc at Harvard focused on determining mechanisms of gene regulation and chromatin dynamics, and she later worked in industry to develop a number of clinical genomic tests.
Biochemist with expertise in transcriptional regulation and method development. During his PhD in the Tijan lab at UC Berkeley, Kevin developed methods to study protein-DNA interactions and identified novel histone gene regulators in Drosophila.
Sequencing aficionado with expertise in microbial ecology. After completing his bachelor's in Molecular Environmental Biology at UC Berkeley, Ian studied a variety of microbial communities and then managed the sequencing core at University of Alaska, Fairbanks.
During her undergrad studies in Human Biology and Masters in Public Health at UVA, Alexa optimized a microfluidic platform for micro-RNA detection in a clinical setting and performed a pilot study for an at-home HPV test.
As an undergraduate at Iowa State University, Febriana worked in a plant metabolism lab and completed her studies in biochemistry.
PULSE@MassChallenge Announces 2018 Cohort of Top Digital Health Startups
DZD selected from over 500 applicants to participate in accelerator
The Refinery announces winners of Fueling the Growth Pitch Competition
DZD wins $15,000 first place award during Women Entrepreneurs Boston event
Life Lab Nurtures Early Stage Startup
DZD featured in Harvard Business School Alumni Bulletin
A Startup Takes on Antibiotic Resistance
DZD Mission Explained by Clifton Leaf, Editor-in-Chief, Fortune
Day Zero Diagnostics is 2017 MedTech Innovator Global Competition Winner
DZD wins $350,000 in non-dilutive funding at the MedTech Innovator Conference
Day Zero Diagnostics Uses Machine Learning Against Antibiotic Resistance
DZD featured in Bostinno
Finalists Announced for Annual MedTech Industry $500K Competition
DZD Selected as one of 4 finalists to compete for cash awards
DZD Announces Completion of $3M Series Seed Raise
Funding to support completion of technical proof of concept and prototype development
The New World Order Of Artificial Intelligence
DZD highlighted in Forbes article on AI trends
MedTech Innovator Announces Startups Selected for Global Accelerator
DZD one of 20 participants in the industry's premier accelerator
MassChallenge Boston Announces 2017 Accelerator Cohort
DZD selected from over 1,500 applicants to participate in program
Finalists Named in Harvard President's Innovation Challenge
DZD named one of 5 healthcare finalists in innovation challenge
Harvard Innovation Labs Story: Miriam Huntley
Miriam interviewed on the Harvard Innovation Labs podcast
Life Lab Builds on Cross-disciplinary Approach
Day Zero Diagnostics featured in opening ceremony of the Pagliuca Harvard Life Lab
Kwon Awarded MGH DOM Innovation Grant
The Kwon Lab wins innovation grant to pursue bacterial resistance diagnostics
Here Are 8 Digital Health Startups to Watch in Boston
BostInno features Day Zero Diagnostics as a startup to watch
Day Zero Diagnostics Named 2016 HBSAB New Venture Competition Winner
DZD wins Harvard Business School Association of Boston Alumni New Venture Contest
Winner, New England Region (2016)
Winner, Pilot Innovation Grant (2016)
Venture in Residence, Harvard iLab & Life Lab (2016-2017)
Audience Choice, MIT Sloan Healthcare Innovation Prize (2017)
Winner, Boston Pitch Competition (2017), Global Competition Winner (2017)
Finalist, Harvard President's Innovation Challenge (2017)
Finalist, MassChallenge Accelerator Program (2017)
Winner, Fueling the Growth Boston Pitch Competition (2017)
Harvard Innovation Lab, Batten Hall, 125 Western Ave, Allston, MA 02163
Copyright © 2017 Day Zero Diagnostics Inc.